Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Proof of Market | Award Amount: 25.00K | Year: 2014
BigDNA is a vaccine development company, using bacteriophages to deliver DNA vaccines. Arising as an additional output from a previous TSB SMART Proof of Concept project, the Company has identified a novel non-vaccine peptide-based cancer therapy which it believes may have significant clinical and commercial potential. This novel peptide combination has the potential to greatly increase clinical efficacy over existing therapies, and may offer a fast track route through to regulatory approval. BigDNA wishes to perform a full analysis of the intellectual property position surrounding this novel therapeutic, as well as a full commercial assessment of the opportunities available to such a product. This will also cover a detailed competitor and licensee analysis. If a positive Proof of Market analysis is obtained, then full technical development of this novel product can begin.
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.1.2-10 | Award Amount: 8.06M | Year: 2012
European aquaculture production provides direct employment to 65.000 people with a turnover of 3 billion . However, the lack of authorised veterinary medicinal products and the consequent disease outbreaks in farmed fish species costs the sector 20% of the production value. The most appropriate method for disease control, both on economical and ethical grounds, is disease prevention by vaccination. TargetFish will advance the development of existing (but not sufficient) and new prototype vaccines against socio-economically important viral or bacterial pathogens of Atlantic salmon, rainbow trout, common carp, sea bass, sea bream and turbot. The project will develop targeted vaccination strategies for currently sub-optimal and for novel vaccines. Improved vaccines will be brought closer to industrial application by addressing practical issues such as efficacy, safety and delivery route. TargetFish will also establish a knowledge- and technology-base for rational development of next generation fish vaccines. To achieve these challenging tasks, we brought together 29 partners from 11 EU member states, 2 associated countries and 1 International Cooperation Partner Country (ICPC). In this large multidisciplinary consortium an approximate equal number of RTD and SME partners will cooperate closely while keeping an intensive communication with the large vaccine and nutrition industries via an Industry Forum. Specifically, TargetFish will 1) generate knowledge by studying antigens and adjuvants for mucosal routes of administration while analyzing the underpinning protective immune mechanisms; 2) validate this knowledge with response assays for monitoring vaccine efficacy and study safety aspects, including those associated with DNA vaccines; 3) approach implementation of prototype vaccines by optimizing vaccination strategies thus 4) shortening the route to exploitation. Thereby, this project will greatly enhance targeted disease prophylaxis in European fish farming.